MedTrace Logo

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

NCT02806024 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-12-03

Study results available
· View outcomes & findings →

Summary

The purpose of this pilot study is to determine if intravenous tranexamic acid (TXA) is effective for reducing blood loss during high risk surgical procedures related to placenta previa and placenta accreta. TXA is currently used in other types of surgery for patients who are expected to have a large blood loss, such as orthopedic or open heart surgery.

Conditions

  • Placenta Accreta
  • Postpartum Hemorrhage
  • Cesarean Section
  • Tranexamic Acid

Interventions

DRUG

Tranexamic Acid

DRUG

Placebo Drug

50 cc Normal Saline IV

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-07-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806024 on ClinicalTrials.gov